IP Library Granted Patent US 12,291,717
Granted Patent B2
US 12,291,717 · App. 16/645,707 · Granted May 6, 2025

RNA replicon for reprogramming somatic cells

Inventors: Marco Alexander Poleganov (Mainz, DE); Mario Perkovic (Mainz, DE); Ugur Sahin (Mainz, DE); Tim Beissert (Mainz, DE)
Assignees: BIONTECH RNA PHARMACEUTICALS GMBH; TRON-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige GMBH
C12N15/86C12N5/0696C12N2501/602C12N2501/603C12N2501/604C12N2501/605C12N2501/606C12N2501/608C12N2506/1307C12N2770/36143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,291,717
App. No.
16/645,707
Granted
May 6, 2025
Kind
B2
Abstract

The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a reprogramming factor. Such RNA replicons are useful for expressing a reprogramming factor in a cell, in particular a somatic cell. Cells engineered to express such reprogramming factors are useful in cell transplantation therapies.

Claims (36)

1. A system comprising:

(i) an RNA construct for expressing a functional alphavirus non-structural protein, and

(ii) an RNA replicon comprising an open reading frame encoding a reprogramming factor and a 5′ replication recognition sequence, wherein the 5′ replication recognition sequence can be recognized by an alphaviral replicase in trans and is characterized in that it does not contain any initiation codons, wherein the 5′ replication recognition sequence does not overlap with a first open reading frame of the RNA replicon, and the initiation codon of the first open reading frame is in the 5′→3′ direction of the RNA replicon and is the first functional initiation codon; wherein

the RNA construct is an mRNA molecule comprising a 5′-cap; and

the RNA replicon does not comprise an open reading frame encoding a functional alphavirus non-structural protein.

2. The system according to claim 1 , wherein the RNA replicon comprises at least one further open reading frame encoding a different reprogramming factor.

3. The system according to claim 1 , wherein the reprogramming factor is selected from the group consisting of OCT4, SOX2, KLF4, c-MYC, LIN28 and NANOG.

4. A method of producing cells having stem cell characteristics comprising the step of introducing into somatic cells a system comprising one or more RNA replicons according to claim 1 .

5. The method according to claim 4 , wherein the one or more RNA replicons encode a set of reprogramming factors.

6. The method according to claim 4 , wherein each of the one or more RNA replicons comprises one open reading frame encoding a reprogramming factor.

7. The method according to claim 4 , wherein the one or more RNA replicons comprise a set of RNA replicons, wherein each of the RNA replicons comprises at least one open reading frame encoding a reprogramming factor and the set of RNA replicons encodes a set of reprogramming factors.

8. A method for providing differentiated cell types comprising the steps of (i) providing cells having stem cell characteristics using the method of claim 4 , and (ii) culturing the cells having stem cell characteristics under conditions that induce or direct partial or complete differentiation to a differentiated cell type.

9. The system according to claim 1 , wherein the RNA replicon further comprises a subgenomic promoter.

10. A system comprising:

(i) an RNA construct for expressing a functional alphavirus non-structural protein, and

(ii) a set of RNA replicons, wherein each of the RNA replicons comprises at least one open reading frame encoding a reprogramming factor and a 5′ replication recognition sequence, wherein the 5′ replication recognition sequence can be recognized by an alphaviral replicase in trans and is characterized in that it does not contain any initiation codons, wherein the 5′ replication recognition sequence does not overlap with a first open reading frame of the RNA replicon, and the initiation codon of the first open reading frame is in the 5′→3′ direction of the RNA replicon and is the first functional initiation codon, and the set of RNA replicons encodes a set of reprogramming factors; wherein

the RNA construct is an mRNA molecule comprising a 5′-cap; and

the RNA replicons do not comprise an open reading frame encoding a functional alphavirus non-structural protein.

11. The system according to claim 10 , wherein each of the RNA replicons comprises one open reading frame encoding a reprogramming factor.

12. The system according to claim 10 , wherein the set of reprogramming factors comprises OCT4 and SOX2.

13. The system according to claim 12 , wherein the set of reprogramming factors further comprises KLF4 and/or c-MYC.

14. The system according to claim 10 , wherein the set of reprogramming factors comprises OCT4, SOX2, NANOG and LIN28.

15. The system according to claim 10 , wherein at least one of the RNA replicons in the set of RNA replicons further comprises a subgenomic promoter.

16. A method for providing cells having stem cell characteristics comprising the steps of:

(i) providing a cell population comprising somatic cells,

(ii) providing an RNA construct for expressing a functional alphavirus non-structural protein, wherein the RNA construct is an mRNA molecule comprising a 5′-cap,

(iii) providing one or more RNA replicons, wherein each of the one or more RNA replicons can be replicated by the functional alphavirus non-structural protein in trans and comprises at least one open reading frame encoding a reprogramming factor and a 5′ replication recognition sequence, wherein the 5′ replication recognition sequence can be recognized by an alphaviral replicase in trans and is characterized in that it does not contain any initiation codons, wherein the 5′ replication recognition sequence does not overlap with a first open reading frame of the one or more RNA replicons, and the initiation codon of the first open reading frame is in the 5′→3′ direction of the one or more RNA replicons and is the first functional initiation codon, wherein the one or more RNA replicons do not comprise an open reading frame encoding a functional alphavirus non-structural protein,

(iv) introducing the RNA construct and the one or more RNA replicons into the somatic cells, such that the cells express a set of reprogramming factors useful in reprogramming somatic cells to cells having stem cell characteristics, and

(v) allowing the development of cells having stem cell characteristics.

17. The method according to claim 16 , wherein at least one of the one or more RNA replicons further comprises a subgenomic promoter.

18. Cells comprising

(i) an RNA construct for expressing a functional alphavirus non-structural protein, and

(ii) an RNA replicon comprising an open reading frame encoding a reprogramming factor and a 5′ replication recognition sequence, wherein the 5′ replication recognition sequence can be recognized by an alphaviral replicase in trans and is characterized in that it does not contain any initiation codons, wherein the 5′ replication recognition sequence does not overlap with a first open reading frame of the RNA replicon, and the initiation codon of the first open reading frame is in the 5′→3′ direction of the RNA replicon and is the first functional initiation codon; wherein

the RNA construct is an mRNA molecule comprising a 5′-cap; and

the RNA replicon does not comprise an open reading frame encoding a functional alphavirus non-structural protein.

19. The cells according to claim 18 , wherein the RNA replicon further comprises a subgenomic promoter.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Sep 20, 2021
From: BIONTECH RNA PHARMACEUTICALS GMBH; BIONTECH SE
To: BIONTECH SE
Reel/Frame 057715/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2020
From: POLEGANOV, MARCO ALEXANDER; PERKOVIC, MARIO; SAHIN, UGUR; BEISSERT, TIM
To: BIONTECH RNA PHARMACEUTICALS GMBH; TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
Reel/Frame 052473/0962 →
Priority Claims (1)
WO PCT/EP2017/073063 · Sep 13, 2017 · international
Continuity (1)
Related Publication 20200277627A1 · Sep 3, 2020
References Cited (24)
US 20090075384A1 · Kamrud · 2009 [cited by examiner]
US 20150159143A1 · Dowdy · 2015 [cited by examiner]
US 20170037376A1 · Pei et al. · 2017 [cited by applicant]
CN 104630136 · 2015 [cited by applicant]
CN 105407922 · 2016 [cited by applicant]
CN 105829525 · 2016 [cited by applicant]
JP 2015519898 · 2015 [cited by applicant]
WO 2008119827 · 2008 [cited by applicant]
WO 2013177133 · 2013 [cited by applicant]
WO 2015014870 · 2015 [cited by applicant]
WO 2015049342 · 2015 [cited by applicant]
WO 2017087763 · 2017 [cited by applicant]
WO 2017162265 · 2017 [cited by applicant]
WO 2017162266 · 2017 [cited by applicant]
Yoshioka, N., & Dowdy, S. F. (2017). Enhanced generation of iPSCs from older adult human cells by a synthetic five-factor self-replicative RNA. PLoS One, 12(7), e0182018. (Year: 2017). [cited by examiner]
Yoshioka, N., Gros, E., Li, H. R., Kumar, S., Deacon, D. C., Maron, C., . . . & Dowdy, S. F. (2013). Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell stem cell, 13(2), 246-254. (Year: 2013). [cited by examiner]
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., . . . & Thomson, J. A. (2007). Induced pluripotent stem cell lines derived from human somatic cells. science, 318(5858), 1917-192… [cited by examiner]
Spuul, P., Balistreri, G., Hellström, K., Golubtsov, A. V., Jokitalo, E., & Ahola, T. (2011). Assembly of alphavirus replication complexes from RNA and protein components in a novel trans-replication system in mammalian… [cited by examiner]
Ou et al. The 5′-Terminal Sequences of the Genomic RNAs of Several Alphaviruses. Journal of Molecular Biology, 1983. 168:1-15. [cited by examiner]
The International Search Report (ISR) with Written Opinion for PCT/EP2018/074486 dated Nov. 8, 2018, pp. 1-12. [cited by applicant]
Yoshioka, Naohisa et al. “Enhanced generation of iPSCs from older adult human cells by a synthetic five-factor self-replicative RNA” Plos One (2017) vol. 12(7), pp. 1-17. [cited by applicant]
Stem Cell Technologies “ReproRNA-OKSGM Non-Integrating Reprogramming Vector” Stem Cell Technologies Dec. 1, 2016 (Dec. 1, 2016). XP002786324, Retrieved from the Internet: URL:https://cdn.stemcell.com/media/files/brochur… [cited by applicant]
EMD Millipore Corporation “SimpliconTM RNA Reprogramming Kit” EMD Millipore Corporation Mar. 1, 2016 XP002786325, Retrieved from the Internet: URL:https:jjwww.merckmillipore.com/NL/en/product/Simplicon-Reprogramming-RNA… [cited by applicant]
Yoshioka, Naohisa et al. “Efficient Generation of Human iPS Cells by a Synthetic Self-Replicative RNA” Cell Stem Cell (2013) vol. 13(2), pp. 246-254. [cited by applicant]